Anti-PD1/PD-L1 immunotherapies have achieved exciting clinical outcomes in several malignancies, such as non-small cell lung cancer (NSCLC), bladder cancer and melanoma. This evidence concerns the gene PDCD1 and urinary bladder carcinoma.